X4 Pharmaceuticals, Inc.
NASDAQ:XFORBiotechnology
+$0.06 today
- Market cap
- $304.30M
- Beta
- 0.37
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.79
Volume 0.64M
Average 0.40M
XFOR Deferred Tax Liabilities
Taxes owed in future periods because of timing differences between accounting and tax rules.
X4 Pharmaceuticals, Inc.NASDAQ: XFOR
Deferred Tax Liabilities · Q1 FY2026 · quarter ended Mar 2026
Deferred tax liabilities remains negative
Q1 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier.
Context
- Deferred tax liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred tax liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Tax Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Tax Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Tax Liabilities vs competitors
How XFOR compares with its peers on the latest reported figures
- XFOR's Mar 2026 deferred tax liabilities of $0 is the highest of the 4 companies compared; the peer median is $0.
- Deferred tax liabilities amounts to 0.0% of total assets for XFOR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $0 | — | — | 0.0% | |
OKUROnKure Therapeutics, Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding XFOR) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for XFOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 81.79M | 121.72M | 99.22M | 55.7M | 217.05M |
| Short-term Investments | 0 | 0 | 15M | 46.36M | 35.95M |
| Net Receivables | 747K | 1.15M | 562K | 1.71M | 573K |
| Inventory | 0 | 0 | 0 | 2.82M | 4.48M |
| Other Current Assets | 5.34M | 5.81M | 7.3M | 5.59M | 3.53M |
| Total Current Assets | 87.88M | 128.68M | 122.08M | 112.18M | 261.58M |
| Property, Plant & Equipment (Net) | 10.22M | 8.33M | 6.4M | 4.84M | 1.59M |
| Goodwill | 17.35M | 17.35M | 17.35M | 17.35M | 17.35M |
| Intangible Assets | 0 | 0 | 0 | 10M | 9.25M |
| Long-term Investments | 1.32M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 402K | 1.23M | 1.44M | 2.08M | 692K |
| Total Non-current Assets | 29.3M | 26.91M | 25.18M | 34.27M | 28.88M |
| Total Assets | 117.18M | 155.59M | 147.26M | 146.45M | 290.46M |
| Account Payables | 4.28M | 7.78M | 8.95M | 8.62M | 5.7M |
| Short-term Debt | 1.87M | 1.32M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 464K |
| Other Current Liabilities | 2.45M | 6.59M | 8.2M | 13.05M | 4.3M |
| Total Current Liabilities | 14.02M | 22.32M | 22.86M | 32.88M | 25.76M |
| Long-term Debt | 33.14M | 32.3M | 54.57M | 75.43M | 76.29M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 621K |
| Other Non-current Liabilities | 826K | 23.3M | 16.12M | 14.59M | 1.5M |
| Total Non-current Liabilities | 38.74M | 59.21M | 73.3M | 91.42M | 78.41M |
| Total Liabilities | 52.76M | 81.54M | 96.16M | 124.3M | 104.17M |
| Common Stock | 28K | 122K | 167K | 6K | 91K |
| Retained Earnings | (282.87M) | (376.74M) | (477.91M) | (515.36M) | (594.55M) |
| Accumulated OCI | (119K) | (119K) | (119K) | (122K) | (109K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 64.41M | 74.05M | 51.1M | 22.15M | 186.29M |
| Total Debt | 39.79M | 38.42M | 58.28M | 78.09M | 77.29M |
| Net Debt | (42M) | (83.3M) | (40.94M) | 22.39M | (139.76M) |
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Intrinsic Alpha fair value
Locked
Current Price
$2.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.